Bristol Myers Squibb’s application to use repotrectinib to treat cancer has been validated by the European Medicines Agency (EMA). This validation marks an important step in the potential approval of repotrectinib as a treatment for cancer. The drug is currently being evaluated for its efficacy and safety in patients with solid tumors that have specific genetic mutations. The validation by the EMA indicates that the application meets necessary regulatory requirements and will now undergo a thorough review process. This development brings hope for improved treatment options for cancer patients in the future.
Source link
Bristol Myers Squibb Repotrectinib application to treat cancer validated by EMA
